SCHEMBL21055754

SCHEMBL21055754

O=c1c2cc(F)ccc2nc(CN(c2ccccc2)c2cccc(CN3CCCC3)c2)n1-c1ccccc1Cl

nearest known ligand 0.70

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21055753 0.87 TDO2 (0.41) HTR7
SCHEMBL6216395 0.83 HTR7 (0.50) HTR7
SCHEMBL8108662 0.81 HTR7 (0.47) HTR7
SCHEMBL21055751 0.80
SCHEMBL6601632 0.79
SCHEMBL8301150 0.75 HTR7 (0.47) HTR7
SCHEMBL735152 0.74
SCHEMBL6215033 0.74 ACP1 (0.46) HTR7
SCHEMBL21055742 0.74
SCHEMBL21055741 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019113110-A2 MODULATION OF AMPA/KAINATE RECEPTORS FOR THE TREATMENT OF HYPOGLYCEMIA VANDERKLISH PETER (US) 2019-06-13 WO disclosed